Current Liabilities
Other accrued liabilities
Bristol-Myers Squibb Other accrued liabilities decreased by 3.0% to $17.58B in Q4 2025 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
Significant changes should be analyzed to determine if they represent one-time adjustments or shifts in operational expense timing.
Detailed definition
This represents miscellaneous short-term obligations that do not fall into standard categories like accounts payable or...
Peer comparison
Standard residual category; peers report this as other current liabilities.
Metric ID:
current_liabilities_other_liabilities_currentHistorical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $18.13B | $17.58B |
| QoQ Change | — | -3.0% |
| YoY Change | — | -3.0% |
Range$17.58B – $18.13B
Avg YoY Growth-3.0%
Median YoY Growth-3.0%
Other accrued liabilities at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's other accrued liabilities?
- Bristol-Myers Squibb (BMY) reported other accrued liabilities of $17.58B in Q4 2025.
- What does other accrued liabilities mean?
- Miscellaneous short-term debts that do not fit into standard categories like accounts payable.